Drug firm Glenmark Pharmaceuticals today said it has received US health regulator's approval to market Mupirocin Calcium Cream, used for treating skin diseases, in the American market.
Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd, has been granted final abbreviated new drug approval from the United States Food and Drug Administration (USFDA) for Mupirocin Calcium Cream USP 2%, Glenmark Pharmaceuticals said in a statement.
"Glenmark will commence shipping immediately," it added.
Glenmark Generics Ltd (GGL) is a subsidiary of Glenmark Pharmaceuticals Ltd and has presence in various global markets including North America.
Mupirocin Calcium Cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible strains of S aureus and S pyogenes.
According to IMS Health sales data for the twelve-month period ending September 2012, the product generated sales of $56.5 million.
Shares of Glenmark Pharmaceuticals were trading at Rs 509 per share on BSE in afternoon trade, down 0.79% from their precious close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app